BioWa

Bio Wa

Biotechnology, 212 Carnegie CTR Ste 101, Princeton, New Jersey, 08540, United States, 1-10 Employees

biowa.com

  • facebook
  • LinkedIn

phone no Phone Number: +16*********

Who is BIOWA

BioWa is a U.S. subsidiary of Kyowa Kirin and the exclusive worldwide licensor of Potelligent Technology, a proprietary technology that creates 100% fucose-free monoclonal antibodies that...

Read More

map
  • 212 Carnegie CTR Ste 101, Princeton, New Jersey, 08540, United States Headquarters: 212 Carnegie CTR Ste 101, Princeton, New Jersey, 08540, United States
  • 2003 Date Founded: 2003
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $5 Million to $10 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2869

checked-icon Does something look wrong? Fix it. | View contact records from BIOWA

BioWa Org Chart and Mapping

Employees

Similar Companies to BioWa

Bristol Myers Squibb

  • 10001+ 10001+
  • 1 Billion and Over $ 1 Billion and Over

Kyowa Kirin, Inc.- U.S.

  • 501-1000 501-1000
  • 100 Million to 250 Million $ 100 Million to 250 Million

Mitsubishi Tanabe Pharma Development America

  • 51-200 51-200
  • 100 Million to 250 Million $ 100 Million to 250 Million
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding BioWa

Answer: BioWa's headquarters are located at 212 Carnegie CTR Ste 101, Princeton, New Jersey, 08540, United States

Answer: BioWa's phone number is +16*********

Answer: BioWa's official website is https://biowa.com

Answer: BioWa's revenue is $5 Million to $10 Million

Answer: BioWa's SIC: 2869

Answer: BioWa has 1-10 employees

Answer: BioWa is in Biotechnology

Answer: BioWa contact info: Phone number: +16********* Website: https://biowa.com

Answer: BioWa is a U.S. subsidiary of Kyowa Kirin and the exclusive worldwide licensor of Potelligent Technology, a proprietary technology that creates 100% fucose-free monoclonal antibodies that demonstrate a marked increase in antibody-dependent cellular cytotoxicity (ADCC). A critical function of the immune system, ADCC enhances the ability of antibodies to kill tumor cells. With BioWas technology, enhancement of monoclonal antibody (Mab) potency has been shown to increase up to 100 fold both in vitro and in vivo.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access